Delving into the Latest Updates on Elemene with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Mechanism-

Therapeutic Areas

Neoplasms

Active Indication

Neoplasms

Inactive Indication-

Originator Organization

Dalianhualijingang Pharmaceutical Co. Ltd.

Active Organization

Dalianhualijingang Pharmaceutical Co. Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

CN (01 Jan 1996),

Neoplasms

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC15H24

InChIKeyOPFTUNCRGUEPRZ-QLFBSQMISA-N

CAS Registry515-13-9

The goal of this phase II randomized clinical trial is to compare the safety and efficacy of Elemene plus Stupp Protocol (the new protocol) and Stupp Protocol alone (the standard protocol) in patients with newly-diagnosed glioblastomas (ndGBMs). The main questions to answer are:
Whether the new treatment protocol (Elemene plus Stupp Protocol) is clinically safe for ndGBM patients.
Whether the new treatment protocol (Elemene plus Stupp Protocol) brings better survival benefits for ndGBM patients compared to the standard-of-care Stupp Protocol.
Study participants will be enrolled in 5 hospitals in China and randomly assigned to receive either the new protocol or the standard protocol. The overall survival (OS) rate in the 12th month, the progression-free survival (PFS) rate in the 6th month, OS, PFS, and adverse events assessed by the CTCAE (Common Terminology Criteria for Adverse Events) will be evaluated for all patients.

Start Date01 May 2023

Sponsor / Collaborator

Peking Union Medical College Hospital

NCT04674527

/ Unknown statusPhase 2IIT

A Pilot Study of Elemene Injectable Emulsion in Treating Patients With Refractory Glioblastoma

This is a pilot phase I study to evaluate the safety and efficacy on elemene injectable emulsion in treating patients with glioblastoma. Elemene, isolated from the Chinese medicinal herb Curcuma wenyujin, was shown to exhibit antitumor activity in human and murine tumor cells in vitro and in vivo.Elemene injectable emulsion against malignant tumors was low. Therefore, the effect of Elemene injectable emulsion being used in clinical settings needs to be confirmed by further RCTs.

Start Date01 Jun 2021

Sponsor / Collaborator

Second Affiliated Hospital Zhejiang University College of

[+1]

ChiCTR2000037148

/ RecruitingNot ApplicableIIT

Clinical study of HIPEC combined with traditional Chinese medicine elemene in the treatment of advanced colorectal cancer

Start Date01 Sep 2020

Sponsor / Collaborator-

100 Clinical Results associated with Elemene

Login to view more data

100 Translational Medicine associated with Elemene

Login to view more data

100 Patents (Medical) associated with Elemene

Login to view more data

536

Literatures (Medical) associated with Elemene

01 Jan 2025·Journal of Ethnopharmacology

Elemene mitigates oxidative stress and neuronal apoptosis induced by cerebral ischemia-reperfusion injury through the regulation of glutathione metabolism

Article

Author: Wu, Pu ; Dong, Xue-Man ; Chen, Lin ; Liu, Yan-Lei ; Ren, Ying-Ying ; Cheng, Long-Hui ; Xu, Yu-Xin ; Zhou, Jian-Liang ; Liu, Zhao-Qian ; Zhang, Hua-Min ; Zhang, Jiu-Long ; Xie, Tian

ETHNOPHARMACOLOGICAL RELEVANCEChinese materia medica (CMM) has a long history and extensive experience in treating ischemic stroke. Wen Ezhu, the rhizome of Curcuma wenyujin Y.H. Chen et C. Ling, is renowned for promoting blood circulation, dispersing blood stasis, alleviating pain, and eliminating masses. Promoting blood circulation and removing blood stasis are essential principles in Traditional Chinese Medicine for treating stroke. Consequently, Wen Ezhu is frequently used in clinical practice as a key CMM for treating stroke. The Elemene active fraction (ELE), a sesquiterpene compound extracted from Wen Ezhu, primarily consists of β-Elemene. It also contains β-Caryophyllene, γ-Elemene, and δ-Elemene isomers. ELE has shown potential pharmacological effects in various diseases, including ischemic stroke. However, its precise mechanism of action in treating stroke remains to be confirmed.AIM OF THE STUDYTo explore the therapeutic potential of ELE in acute ischemic stroke and elucidate its underlying mechanisms.MATERIALS AND METHODSA rat model of middle cerebral artery occlusion reperfusion (MCAO/R) was used to evaluate ELE's effects. Therapeutic efficacy was assessed through mNSS scoring, magnetic resonance imaging (MRI), tetrazolium chloride (TTC) staining, Hematoxylin and eosin (H&E), and Nissl staining. Non-targeted metabolomics identified key pathways, confirmed using biochemical analysis, immunohistochemistry, and Western blotting. ROS levels and apoptosis-related proteins were also evaluated.RESULTSOur findings show that ELE administration significantly reduced the cerebral infarct area and lowered modified neurological severity scores (mNSS) in animals, indicating a strong neuroprotective effect. Metabolomics results highlight the glutathione (GSH) metabolic pathway as a key mechanism through which ELE exerts its therapeutic effects. Specifically, ELE upregulates glutathione reductase (GR) protein expression and downregulates glutathione peroxidase (GPX) expression. The regulatory process of ELE decreases oxidized glutathione (GSSG) levels and increases GSH levels, effectively reducing oxidative stress damage (lower reactive oxygen species levels) during CI/RI. This results in the downregulation of the pro-apoptotic protein Bax and the upregulation of the pro-survival protein Bcl-2, thus reducing neuronal apoptosis.CONCLUSIONSELE protects neurons in MCAO/R rats through the GSH metabolism pathway, balancing GSH and GSSG levels to mitigate oxidative stress and enhance neuroprotection in cerebral ischemia/reperfusion injury.

01 Jan 2025·EXPLORE

A meta-analysis of randomized controlled trials examining the efficacy and safety of elemene in combination with chemotherapy for the treatment of gastric cancer

Review

Author: Rastogi, Sanjay ; Huang, Yanhua ; Chen, Bo ; Du, Feng ; Liu, Yige

BACKGROUNDElemene is a naturally occurring chemical derived from plants of the Zingiberaceae family, and it finds application in several cancer-related contexts. Nevertheless, there is a dearth of comprehensive assessment about the combined effectiveness and safety of chemotherapy in gastric cancer (GC).OBJECTIVETo investigate the safety and effectiveness of elemene in conjunction with chemotherapy for the treatment of Gastric cancer.METHODSA comprehensive search of Medline, EMBASE, Scopus, and Cochrane Library identified peer-reviewed journal papers. OR and RR were calculated, along with their 95 % confidence ranges. We assessed heterogeneity using Cochrane Q and I2 statistics and the relevant P-value. The analysis used RevMan 5.3.RESULTSCurrent meta-analysis includes 11 RCTs with 726 GC patients, 364 of whom received elemene paired with treatment and 362 received standard chemotherapy. Elemene-coated chemotherapy improves ORR (RR 1.43, 95 % CI 1.22-1.67, p < 0.00001), reduces blood system toxicity (OR 0.49, 95 % CI 0.35-0.69, p < 0.0001), nausea and vomiting (RR 0.65, 95 % CI 0.55-0.77), diarrhea (RR 0.73, 95 % CI 0.58-0.90), and liver problems (RR 0.64, 95 % CI 0.49-0.83).Subgroup analysis showed that both oral and intravenous administration improved ORR statistically, and a network diagram with consistent connectivity, well-defined network architecture, and high-quality evidence shows that elemene combined with chemotherapy has significant therapeutic efficacy.CONCLUSIONElemene may possess the capacity to enhance the effectiveness and mitigate the adverse effects of gastric cancer chemotherapy. Nevertheless, due to the restricted number of studies incorporated, additional research studies utilizing sizable samples are required to validate the aforementioned findings.

01 Jan 2025·Journal of Ethnopharmacology

β-elemene, a sesquiterpene constituent from Curcuma phaeocaulis inhibits the development of endometriosis by inducing ferroptosis via the MAPK and STAT3 signaling pathways

Article

Author: Zheng, Weilin ; Liu, Hao ; Cao, Lixing ; Kuang, Yanqi ; Fu, Zhiyi ; Yang, Jiumei ; Luo, Meicheng

ETHNOPHARMACOLOGICAL RELEVANCEThe rhizome of Curcuma phaeocaulis Valeton, Curcuma wenyujin Y.H. Chen & C. Ling, or Curcuma kwangsiensis S. G. Lee et C. F. Liang, commonly known as Wen-E-Zhu and E'zhu, has been utilized in traditional Chinese medicine for the treatment of cancer and gynecological diseases since antiquity. This traditional medicinal herb is highly esteemed for its efficacy in promoting blood circulation, dissolving blood stasis, reducing swelling, and alleviating pain. β-Elemene (β-ELE), a sesquiterpene compound derived from Curcuma phaeocaulis, has demonstrated potential in inhibiting tumor cell proliferation and inducing ferroptosis, which have been extensively studied in various malignant neoplasms. Previous studies have confirmed that Sparganium stoloniferum-Curcuma phaeocaulis containing β-ELE may possess anti-endometriotic properties. However, the exact mechanism underlying β-ELE's anti-endometriosis activity remains largely unknown and requires further research and investigation.AIM OF THE STUDYTo identify the anti-endometriosis target of β-ELE and elucidate the underlying molecular mechanism of β-ELE in endometriosis, focusing on inducing ferroptosis.MATERIALS AND METHODSThe target pathway of β-ELE in endometriosis treatment was predicted through network pharmacology and bioinformatics analysis. Surface plasmon resonance-high performance liquid chromatography-protein mass spectrometry (SPR-HPLC-MS) and molecular docking were used to further identify the potential targets of β-ELE in endometriosis. The immortalized endometriosis epithelial cell line 12Z was used for in vitro study. The effect of β-ELE on cell proliferation and migration was detected by CCK-8, EdU and wound healing assay, and ultrastructural changes were examined via transmission electron microscopy. The effect of β-ELE-induced ferroptosis was determined by western blot, immunohistochemistry staining and flow cytometry. SPR affinity analysis was performed to specific the direct interaction between β-ELE and FTH1, FTL, GPX4, STAT3 and MAPK14. To establish a mouse model of endometriosis and to assess the inhibitory effects of β-ELE and ELE injection on endometriosis in vivo as well as safety profile of administration, and investigate the effects and underlying mechanisms of β-ELE and Elemene injection on ferroptosis in ectopic lesions.RESULTSSPR-HPLC-MS was employed to identify 76 potential targets of β-ELE for endometriosis treatment, closely linked to ferroptosis. Molecular docking revealed that glutathione peroxidase 4 (GPX4), ferritin heavy chain 1 (FTH1), ferritin light chain (FTL), signal transducer and activator of transcription 3 (STAT3), and mitogen-activated protein kinase 14 (MAPK14) are key action targets of β-ELE in endometriosis. Further investigations revealed that β-ELE inhibited the proliferation and migration of endometriotic cells in vitro while inducing ferroptosis, as evidenced by increased levels of iron, reactive oxygen species (ROS), and lipid peroxidation. In a mouse model, β-ELE inhibited the growth of endometriotic lesions, induced ferroptosis, suppressed fibrosis, and exhibited anti-endometriotic effects. Mechanistically, β-ELE downregulates the expression levels of GPX4, FTH1, and FTL and inhibited the phosphorylation of STAT3 and MAPK14, which may elucidate its underlying molecular mechanisms.CONCLUSIONThis study demonstrates that the inhibitory effect of β-ELE on endometriosis by inducing ferroptosis in vitro and in vivo. Our results revealed that β-ELE exerts anti-endometriosis effects by inducing ferroptosis via the MAPK and STAT3 signaling pathways.

100 Deals associated with Elemene

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Elemene	L01XX	-

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Neoplasms	CN	Dalianhualijingang Pharmaceutical Co. Ltd.	01 Jan 1996

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


CSCO2022	Not Applicable	Malignant ascites	42	榄香烯乳状注射液	nugsnboxqq(lxkdrjvjdk) = jftymnodju qbsnasfckj (lnubdouwpu )	Positive	21 Sep 2022
CSCO2021	Not Applicable	Esophageal Carcinoma	50	榄香烯 (单放组)	uiohzbgxcc(ojifstwrcv) = kyogjpxbny qnrjwsulja (fohxbveenp ) View more	-	25 Sep 2021
				榄香烯 (综合组)	uiohzbgxcc(ojifstwrcv) = ddkszudxso qnrjwsulja (fohxbveenp ) View more
CSCO2021	Not Applicable	Liver Cancer	60	榄香烯注射液联合放疗	nphwwxvnmp(bacurnbeqw) = tkwhdbctzy husrhxvquh (fjqpyeyblp ) View more	Positive	25 Sep 2021
				榄香烯注射液 (单纯放疗)	nphwwxvnmp(bacurnbeqw) = ouiwmofgdu husrhxvquh (fjqpyeyblp )
CSCO2021	Not Applicable	-	65	榄香烯注射液联合TMZ(替莫唑胺)	jihcctbqgu(pzvmazkxgv) = abaewxwlsa tekozkfvfb (abajvclemt )	Positive	25 Sep 2021
				单TMZ组	jihcctbqgu(pzvmazkxgv) = lygfpeywpj tekozkfvfb (abajvclemt )
CSCO2021	Not Applicable	HER2 negative Gastric Cancer	66	榄香烯口服乳+奥沙利铂+替吉奥	(dglintlkff) = oiijfewwll fjraimhnot (nwrzjirems ) View more	Positive	25 Sep 2021
				奥沙利铂+替吉奥	(dglintlkff) = guyjmmrtrt fjraimhnot (nwrzjirems ) View more
CSCO2020	Not Applicable	Non-Small Cell Lung Cancer \| Brain metastases	90	榄香烯注射液联合全脑放疗	dqvvjycher(ivulrfjbgt) = gnecnizkwt dzxzxugmef (mjsrrasszm ) View more	-	19 Sep 2020
				榄香烯注射液 (全脑放疗)	dqvvjycher(ivulrfjbgt) = hpanrweosu dzxzxugmef (mjsrrasszm ) View more
CSCO2020	Not Applicable	Hypopharyngeal Carcinoma	56	榄香烯口服乳	tisetulrxs(bdockutnax) = pgbfnkyscx gybjyoetsg (iqyozpduze ) View more	Positive	19 Sep 2020
				同步放化疗	tisetulrxs(bdockutnax) = jsmjaojfsb gybjyoetsg (iqyozpduze ) View more
CSCO2020	Not Applicable	Liver Cancer	60	榄香烯注射液联合介入化疗	vngpyfamqb(gvdhjemupg) = 榄香烯组明显减轻，两组比较差异有统计学意义(P<0.05) bsdtyaileb (dtkrsubvmr ) View more	-	19 Sep 2020
				榄香烯注射液 (介入化疗)
CSCO2020	Not Applicable	Malignant ascites	42	腹腔灌注榄香烯注射液	xyqseqnuoc(kysaniuwyf) = qyaaenpvgs xnbbfrqakk (jgcyhmyflh )	Positive	19 Sep 2020
CSCO2020	Not Applicable	Advanced gastric carcinoma	50	榄香烯口服乳	(pfqqiqzlns) = newzrmmnqh obyzazzmuo (vnomvglixy ) View more	Positive	19 Sep 2020
				榄香烯 (最佳支持治疗)	(pfqqiqzlns) = lejsjrvgqq obyzazzmuo (vnomvglixy )